> 450            original publications (peer reviewed)

> 100            overviews and textbooks articles

Unger M, Belke M, Hattemer K, Stiasny-Kolster K, Keil B, Rosenow F, Heverhagen J, Diederich N, Mayer G, Möller J, Oertel WH, Knake S. Selective microstructural changes in the brainstem, substantia nigra, olfactory region and other brain areas of patients with idiopathic rapid eye movement (REM) sleep behaviour disorder (RBD). Sleep 2010; 33 (6): 767-773

Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, Daniels C, Deutschlander A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J; German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006 Aug 31;355(9):896-908

Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, and Schwarz J. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord. 2006 Mar;21(3):343-53

Oertel WH, Benes H, Bodenschatz R, Peglau I, Warmuth R, Happe S, Geisler P, Cassel W, Leroux M, Kohnen R, Stiasny-Kolster K. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology. 2006 Sep 26;67(6):1040-1046

Stamelou M, Pilatus U, Reuss A, Magerkurth J, Eggert KM, Schade-Brittinger C, Oertel WH, Höglinger GU. Combined ³¹P- and ¹H-magnetic resonance spectroscopy provides first in vivo  evidence for cerebral ATP depletion in progressive supranuclear palsy J Cereb Flow Metabol 2009; 29 (4): 861-870

Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, and Dodel R.. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005;23(8):817-836

Höglinger GU, Lannuzel A, Escobar Khondiker M, Michel PP, Duyckaerts C, Féger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC. The Mitochondrial Complex I Inhibitor Rotenone Triggers a Cerebral Tauopathy. J. Neurochem., 2005;95:930-939

Stiasny-Kolster K, Dörr Y, Möller JC, Höffken H, Behr TM, Oertel WH, Mayer G. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128: 126-137

Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wei X, Farlow M, Sommer N, Oertel WH (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75(10):1472-1474

Höglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neuroscience, 2004;7:726-735

Höglinger GU, Rissling I, Metz A, Ries V, Heinermann A, Prinz H, Spieker S, Deuschl G, Baum E, Oertel WH. Enhancing recognition of early Parkinsonism in the community. Mov Disord 2004;19:505-512

Stiasny-Kolster K, Magerl W, Oertel W, Moeller JC, Treede RD. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 2004; 127:773-782